(Q28297557)

2

object named as

Arnold S Monto

0 references

Paul Kay-Sheung Chan

3

0 references

author name string

Thomas D Szucs

4

0 references

Karl G Nicholson

Lancet Infectious Diseases

5

0 references

language of work or name

English

0 references

publication date

October 2008

0 references

published in

0 references

volume

8

0 references

issue

10

0 references

page(s)

650-8

0 references

cites work

Updating the Accounts: Global Mortality of the 1918-1920 "Spanish" Influenza Pandemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Avian influenza A (H5N1).

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Effect of neuraminidase antibody on Hong Kong influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

The origin of the 1918 pandemic influenza virus: a continuing enigma.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Preparing for pandemic vaccination: an international policy agenda for vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Preparing for the next pandemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

1918 Influenza: the mother of all pandemics

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

H5N1 outbreaks and enzootic influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Avian influenza virus infections in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Priority setting for pandemic influenza: an analysis of national preparedness plans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Pandemic influenza preparedness in the Asia-Pacific region

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

How prepared is Europe for pandemic influenza? Analysis of national plans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Vaccines and antiviral drugs in pandemic preparedness

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

UK stocks up on antiviral drug to tackle flu outbreak

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

The genesis and spread of reassortment human influenza A/H3N2 viruses conferring adamantane resistance

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Vaccines for seasonal and pandemic influenza.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Purified influenza A virus N2 neuraminidase vaccine is immunogenic and non-toxic in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Emerging infections: pandemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Public health. Will vaccines be available for the next influenza pandemic?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Mitigation strategies for pandemic influenza in the United States.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

The macro-epidemiology of influenza vaccination in 56 countries, 1997--2003.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Pre-emptive vaccination against pandemic influenza virus

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Vaccines against avian influenza--a race against time

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Vaccines for pandemic influenza

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Pandemic preparedness: lessons learnt from H2N2 and H9N2 candidate vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Safety and immunogenicity of an inactivated split-virion influenza A/Vietnam/1194/2004 (H5N1) vaccine: phase I randomised trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Effects of adjuvants on the safety and immunogenicity of an avian influenza H5N1 vaccine in adults

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Cross-reactivity to highly pathogenic avian influenza H5N1 viruses after vaccination with nonadjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a potential priming strategy.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Evaluation of the safety and immunogenicity of a booster (third) dose of inactivated subvirion H5N1 influenza vaccine in humans

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Pre- or post-pandemic influenza vaccine?

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Live, attenuated influenza A H5N1 candidate vaccines provide broad cross-protection in mice and ferrets

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Prospects for universal influenza virus vaccine

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Safety and immunogenicity of a baculovirus-expressed hemagglutinin influenza vaccine: a randomized controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Containing pandemic influenza at the source.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Strategies for mitigating an influenza pandemic

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Vaccination strategies for an influenza pandemic.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

An epidemiologic and clinical evaluation of Guillain-Barré syndrome reported in association with the administration of swine influenza vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans.

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

Prioritization strategies for pandemic influenza vaccine in 27 countries of the European Union and the Global Health Security Action Group: a review

1 reference

https://api.crossref.org/works/10.1016%2FS1473-3099%2808%2970232-9

7 January 2021

10.1016/S1473-3099(08)70232-9

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

125376

125376

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference